What the research actually shows.
Evidence summaries for peptides and related compounds — what the studies found, what they did not, and how strong the evidence actually is. We sell nothing, so no page here has a reason to overstate a finding.
- Compounds covered
- 0
- Evidence grades
- 0
- Products sold
- 0
Not everything with "peptide" in the name
has the same evidence behind it.
Some of the compounds people discuss interchangeably are licensed medicines tested in tens of thousands of participants. Others have never been given to a human being under controlled conditions. A few were tested and did not work.
Forum threads and sellers flatten all of that into one category. This site separates it back out — compound by compound, with the studies linked so you can check us.
- Compounds covered
- 0
- Are approved medicines
- 0
- Have no human trials at all
- 0
- Were tested and failed
- 0
Start with the evidence
Each page sets out what the research found, what it did not, the reported risks, and the regulatory position — with the primary literature linked throughout.
Semaglutide
A long-acting analogue of GLP-1, a hormone the gut releases after eating. Structural changes — an Aib substitution that resists enzymatic breakdown, and a fatty acid chain that binds albumin — extend its half-life from minutes to about a week.
Read the evidenceTirzepatide
A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions that resist degradation and a fatty acid chain for weekly dosing.
Read the evidenceRetatrutide
An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it, and is intended to raise energy expenditure alongside the appetite suppression the other two provide.
Read the evidenceMelanotan II
A synthetic cyclic analogue of alpha-MSH developed at the University of Arizona in the 1980s. Unlike its relative Melanotan I it is non-selective, activating melanocortin receptors across subtypes, which is the source of both its effects and its problems.
Read the evidenceGHK-Cu
A naturally occurring tripeptide that binds copper, first isolated from human plasma in the 1970s. Plasma levels decline with age, which is the observation most claims about it are built on. It is a cosmetic ingredient, not a medicine.
Read the evidenceBPC-157
A synthetic peptide corresponding to a partial sequence of a protein found in human gastric juice. It is among the most discussed compounds in this space and among the least supported by human evidence.
Read the evidenceSeven levels, plainly labelled
The grade reflects the best available human evidence. It is not a recommendation, and a high grade does not mean a compound is appropriate for anyone in particular.
Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.
Large randomised trials in humans are complete or under way, but the compound is not licensed. Efficacy and common adverse effects are reasonably well characterised; long-term safety may not be.
Tested in humans for efficacy at a modest scale. Enough to show a signal and characterise short-term tolerability, not enough to establish safety or durability. Most compounds that reach this stage still fail.
Studied in small numbers of humans, usually for safety and pharmacokinetics rather than whether it works. A phase 1 result says almost nothing about effectiveness.
Evidence comes from rodents or other animal models, with no published controlled human trials. Most compounds that look promising in animals do not replicate in people — the attrition rate from animal model to approved drug is well over 90%.
Evidence comes from cell culture or biochemical assays. This can establish that a compound does something to cells in a dish. It establishes nothing about what it does in a living body.
Taken into human trials and did not outperform placebo on its primary endpoint, or development was discontinued. This is stronger evidence than "untested" — it is evidence of absence, not absence of evidence.
How these pages are written
Limitations get equal billing
Every compound page has a section headed "what the evidence does not show", and it is as prominent as the findings. A summary that only lists positive results is marketing, whatever it calls itself.
Evidence is graded, not implied
Each compound carries a grade from "approved medicine" down to "laboratory studies only". Volume of literature does not raise the grade — a thousand mouse papers is still animal evidence.
Negative results are reported
Compounds that went into human trials and failed are listed as failed. That is more useful than silence, and it is information sellers have no reason to give you.
No dosing, ever
We describe what studies found, not how to use anything. No doses, no routes, no protocols — not on request either. That is the line between an information resource and something else.
We don't sell anything
Genexis Health Ltd. holds no stock, takes no orders and arranges no supply. There is no price list on this site and no enquiry that leads to a sale. That is deliberate — an information resource with something to sell is an advertisement, and it should be read as one.
Several compounds described here are prescription-only medicines. Several more are investigational products no regulator has approved. If you are considering any of them, the conversation to have is with a doctor, not with a supplier.
- No products, no prices, no stock
- No dosing or administration guidance
- Limitations published alongside findings
- Primary literature linked throughout
- Corrections welcomed and acted on
Discussion, harm reduction and questions
Our Telegram and Instagram are where the discussion happens — safer practice, reading the literature, and questions about what the evidence does and doesn't support. No selling, and no dosing advice there either.
Join the discussion@genexishealthInformation only. Everything on this site is a summary of published research, provided for general information. It is not medical advice, not a treatment recommendation, and not a substitute for consultation with a qualified healthcare professional. Genexis Health does not sell, supply or arrange the supply of any compound described here. Many of the compounds covered are prescription-only medicines, investigational products that no regulator has approved, or substances regulators have issued public warnings about. Nothing here should be read as suggesting any of them is safe or appropriate for you to use.